Efficacies of Hybrid and High-dose Dual Therapies for the First-line Anti-H Pylori Treatment

NACompletedINTERVENTIONAL
Enrollment

240

Participants

Timeline

Start Date

September 1, 2018

Primary Completion Date

November 30, 2021

Study Completion Date

February 28, 2022

Conditions
Helicobacter Pylori Infection
Interventions
DRUG

Pariet

Rabeprazole 20 mg and amoxicillin 750 mg qid for 14 days

DRUG

Amolin

Rabeprazole 20 mg and amoxicillin 750 mg qid for 14 days

DRUG

Klaricid

Rabeprazole 20 mg and amoxicillin 1 g bid. for 7 days, followed by rabeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg, and metronidazole 500 mg bid. for 7 days

DRUG

Flagyl

Rabeprazole 20 mg and amoxicillin 1 g bid. for 7 days, followed by rabeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg, and metronidazole 500 mg bid. for 7 days

Trial Locations (1)

83300

Chang Gung Memorial Hospital, Kaohsiung City

All Listed Sponsors
lead

Chang Gung Memorial Hospital

OTHER

NCT05152004 - Efficacies of Hybrid and High-dose Dual Therapies for the First-line Anti-H Pylori Treatment | Biotech Hunter | Biotech Hunter